학술논문
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses
Document Type
article
Author
Ane Ogbe; Barbara Kronsteiner; Donal T. Skelly; Matthew Pace; Anthony Brown; Emily Adland; Kareena Adair; Hossain Delowar Akhter; Mohammad Ali; Serat-E Ali; Adrienn Angyal; M. Azim Ansari; Carolina V. Arancibia-Cárcamo; Helen Brown; Senthil Chinnakannan; Christopher Conlon; Catherine de Lara; Thushan de Silva; Christina Dold; Tao Dong; Timothy Donnison; David Eyre; Amy Flaxman; Helen Fletcher; Joshua Gardner; James T. Grist; Carl-Philipp Hackstein; Kanoot Jaruthamsophon; Katie Jeffery; Teresa Lambe; Lian Lee; Wenqin Li; Nicholas Lim; Philippa C. Matthews; Alexander J. Mentzer; Shona C. Moore; Dean J. Naisbitt; Monday Ogese; Graham Ogg; Peter Openshaw; Munir Pirmohamed; Andrew J. Pollard; Narayan Ramamurthy; Patpong Rongkard; Sarah Rowland-Jones; Oliver Sampson; Gavin Screaton; Alessandro Sette; Lizzie Stafford; Craig Thompson; Paul J. Thomson; Ryan Thwaites; Vinicius Vieira; Daniela Weiskopf; Panagiota Zacharopoulou; Oxford Immunology Network Covid-19 Response T Cell Consortium; Oxford Protective T Cell Immunology for COVID-19 (OPTIC) Clinical Team; Lance Turtle; Paul Klenerman; Philip Goulder; John Frater; Eleanor Barnes; Susanna Dunachie
Source
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Subject
Language
English
ISSN
2041-1723
Abstract
Understanding the immune response to SARS-CoV-2 is dependent on being able to distinguish COVID-19 immune responses from cross-reactive immune responses to other coronaviruses. Here the authors show that choice of antigens and whether an ICS, ELISPOT or T cell proliferation assay is used has a major effect on this discriminatory ability.